IFM Investors Pty Ltd - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
IFM Investors Pty Ltd ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$1,903,646
-15.1%
27,966
+1.8%
0.02%
-13.8%
Q2 2023$2,242,948
+13.5%
27,477
+3.2%
0.03%
-3.3%
Q1 2023$1,976,125
-3.5%
26,636
+7.8%
0.03%
-11.8%
Q4 2022$2,048,794
+16.7%
24,720
+300.0%
0.03%
+6.2%
Q3 2022$1,755,000
-18.1%
6,1800.0%0.03%
-15.8%
Q2 2022$2,142,000
-15.4%
6,180
+5.6%
0.04%
-2.6%
Q1 2022$2,533,000
-0.7%
5,850
+18.7%
0.04%
-17.0%
Q4 2021$2,550,000
+5.2%
4,930
-1.5%
0.05%
-6.0%
Q3 2021$2,425,000
+7.6%
5,0050.0%0.05%
+8.7%
Q2 2021$2,254,0005,0050.05%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Blue Water Life Science Advisors, LP 46,500$16,119,0008.75%
Montanaro Asset Management Ltd 93,950$32,567,0004.90%
Jackson Square Partners, LLC 556,157$192,786,0004.50%
STONE RUN CAPITAL, LLC 22,405$7,767,0003.91%
Ownership Capital B.V. 655,654$227,276,0003.90%
Brown Capital Management 839,587$291,034,0003.90%
Sandhill Capital Partners LLC 97,382$33,757,0003.61%
DF DENT & CO INC 684,026$237,111,0003.34%
Westwind Capital 27,946$9,687,0003.17%
MAIRS & POWER INC 655,930$227,371,0002.72%
View complete list of BIO-TECHNE CORP shareholders